ORKA

Oruka Therapeutics, Inc. (ORKA) - Q2 2026 Filing Summary

Business Context and Reporting Period

Oruka Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis and other inflammatory and immunology indications. This summary covers the quarterly period ended June 30, 2026. The company has no approved products and has not generated any revenue from product sales to date.

Key Financial Metrics

Material Changes vs. Prior Period

• Increased Operating Burn: Total operating expenses increased by 76% ($21.7 million) in Q2 2026 compared to Q2 2025, driven primarily by a 80% increase in R&D expenses. YTD 2026 operating expenses rose 62% compared to YTD 2025.
• R&D Drivers: The increase in R&D expenses is attributed to higher external costs for clinical trials (CROs/CMOs), a $5.0 million upfront payment to Halozyme for a collaboration agreement, and increased personnel costs. This was partially offset by the absence of certain milestone expenses recorded in the prior year.
• Capital Raising: In April 2026, the company completed an underwritten public offering, raising net proceeds of $658.3 million. Additionally, the company raised $38.9 million through its At-The-Market (ATM) program during the first half of 2026.
• Liquidity Position: Cash and marketable securities increased significantly from $477.4 million at December 31, 2025, to $1.12 billion at June 30, 2026, due to the equity offerings.

Outlook, Risks, and Management Commentary

• Clinical Pipeline Progress:
  • ORKA-001 (IL-23p19): Phase 2a (EVERLAST-A) data presented in April 2026 showed 63.5% of participants achieved PASI 100 at Week 16. Phase 2b (EVERLAST-B) is ongoing, with data expected in Q4 2026. Phase 3 initiation is planned for H1 2027.
  • ORKA-002 (IL-17A/F): Phase 1 results support a half-life of 75-80 days. Phase 2 trials in Psoriasis (ORCA-SURGE) and Hidradenitis Suppurativa (ORCA-SPLASH) are ongoing, with data expected in Q1 2027.
• Liquidity Outlook: Management expects existing cash and marketable securities to fund operations for at least 12 months from the filing date. The company anticipates continued significant losses as it advances clinical trials.
• Key Risks:
  • Capital Requirements: The company will need to raise substantial additional capital to fund future operations, which may result in dilution.
  • Regulatory & Clinical Risk: No products are approved; success depends on clinical trial outcomes and regulatory approvals, which are uncertain.
  • Third-Party Reliance: The company relies on third parties for manufacturing (including WuXi Biologics) and clinical trials. Geopolitical tensions and the BIOSECURE Act pose potential supply chain risks.
  • Intellectual Property: The company relies on licensed technology from Paragon Therapeutics; disputes or loss of rights could be material.

Investor Verification Checklist

• Cash Runway: Verify the specific monthly burn rate and confirm the 12-month liquidity runway assertion given the increased operating expenses.
• ORKA-001 Data: Review the full Week 16 data from the EVERLAST-A trial and monitor the upcoming Week 28 and Week 52 data releases for durability of response.
• Manufacturing Supply Chain: Assess the impact of the BIOSECURE Act and potential tariffs on the company's reliance on WuXi Biologics for manufacturing.
• Halozyme Collaboration: Confirm the terms and strategic value of the $5.0 million upfront payment and the Hypercon technology integration.
• Dilution Risk: Monitor the remaining capacity under the ATM program ($160.3 million as of June 30, 2026) and potential future equity issuances.